1. To Make More Covid-19 Vaccines, Rival Drugmakers Team Up  The Wall Street Journal
  2. Vaccine makers Pfizer and Moderna pledge massive boost to U.S. supply after sluggish rollout  The Washington Post
  3. Moderna moves forward on plan to increase Covid vaccine supply in each vial after latest FDA feedback  CNBC
  4. The Guardian view on Boris Johnson's Covid plan: a risky bet on vaccines  The Guardian
  5. Wayne County targeting COVID-19 vaccines for seniors in 8 communities  WXYZ-TV Detroit | Channel 7
  6. View Full Coverage on Google News

GlaxoSmithKline and Sanofi on Monday announced the start of a new Phase 2 trial involving their protein-based COVID-19 vaccine candidate after facing a setback in December.GlaxoSmithKline and Sanofi on Monday announced the start of a new Phase 2 trial involving their protein-based COVID-19 vaccine candidate after facing a setback in December.

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50 years.The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50 years.

Sanofi, GlaxoSmithKline start new COVID vaccine study

Britain's GlaxoSmithKline and France's Sanofi on Monday said they had started a new clinical trial of their protein-based Covid-19 vaccine candidate.Britain's GlaxoSmithKline and France's Sanofi on Monday said they had started a new clinical trial of their protein-based Covid-19 vaccine candidate.

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year.Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year.

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate New Phase 2 study assesses potential...Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate New Phase 2 study assesses potential...

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate Paris Stock Exchange:SAN

GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch. In December, the two groups stunned investors when they said their vaccine would be delayed towards the end of 2021 after clinical trials showed an insufficient immune response in older people. Disappointing results were probably caused by an inadequate concentration of the antigen used in the vaccine, Sanofi and GSK said, adding that Sanofi has also started work against new coronavirus variants to help plan their next steps.GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch. In December, the two groups stunned investors when they said their vaccine would be delayed towards the end of 2021 after clinical trials showed an insufficient immune response in older people. Disappointing results were probably caused by an inadequate concentration of the antigen used in the vaccine, Sanofi and GSK said, adding that Sanofi has also started work against new coronavirus variants to help plan their next steps.

GSK and Sanofi start with new COVID-19 vaccine study after setback

GlaxoSmithKline and Sanofi have started a clinical trial of a Covid-19 vaccine candidate after a setback at the end of last year.A trial involving 720 volunteers aged 18 and over in the United StatesGlaxoSmithKline and Sanofi have started a clinical trial of a Covid-19 vaccine candidate after a setback at the end of last year.A trial involving 720 volunteers aged 18 and over in the United States

Bloomberg - Are you a robot?

 “We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data"

GlaxoSmithKline PLC and Sanofi SA to push ahead with phase II trial of Covid-19 vaccine

The companies aim to reach final testing in the second quarter, and if the results are conclusive, hope to see the vaccine approved by the fourth quarter

GSK, Sanofi begin new COVID-19 vaccine study after setback - Express Pharma